已发表论文

发挥黄芪甲苷 IV 在对抗呼吸道疾病方面的潜力

 

Authors Tan J, Yi J, Cao X, Wang F, Xie S, Dai A

Received 6 April 2023

Accepted for publication 20 June 2023

Published 3 July 2023 Volume 2023:17 Pages 1963—1978

DOI https://doi.org/10.2147/DDDT.S416091

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Jianbo Sun

Abstract: Respiratory diseases are an emerging public health concern, that pose a risk to the global community. There, it is essential to establish effective treatments to reduce the global burden of respiratory diseases. Astragaloside IV (AS-IV) is a natural saponin isolated from Radix astragali (Huangqi in Chinese) used for thousands of years in Chinese medicine. This compound has become increasingly popular due to its potential anti-inflammatory, antioxidant, and anticancer properties. In the last decade, accumulated evidence has indicated the AS-IV protective effect against respiratory diseases. This article presents a current understanding of AS-IV roles and mechanisms in combatting respiratory diseases. The ability of the agent to suppress oxidative stress, cell proliferation, and epithelial-mesenchymal transition (EMT), to attenuate inflammatory responses, and modulate programmed cell death (PCD) will be discussed. This review highlights the current challenges in respiratory diseases and recommendations to improve disease management.
Keywords: astragaloside IV, Radix astragali , respiratory diseases, oxidative stress, inflammatory responses